AR045959A1 - Derivados de pirazolo- e imidazo-pirimidina - Google Patents
Derivados de pirazolo- e imidazo-pirimidinaInfo
- Publication number
- AR045959A1 AR045959A1 ARP040103565A ARP040103565A AR045959A1 AR 045959 A1 AR045959 A1 AR 045959A1 AR P040103565 A ARP040103565 A AR P040103565A AR P040103565 A ARP040103565 A AR P040103565A AR 045959 A1 AR045959 A1 AR 045959A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- unsubstituted
- cycloalkyl
- alkyl
- halogen
- Prior art date
Links
- 229910052739 hydrogen Inorganic materials 0.000 abstract 10
- 239000001257 hydrogen Substances 0.000 abstract 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 8
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical group 0.000 abstract 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 239000011737 fluorine Substances 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- AIDS & HIV (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Otolaryngology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composiciones farmacéuticas que contienen dichos derivados y a su utilización en la prevención y tratamiento de enfermedades. Reivindicación 1: Un compuesto de la fórmula (1), en la que: A es =C(R4)-; D es =C(R5)-; E es =C(R6)-; o uno de A, D y E es =N-; L es =N- o =C(H)-; M es =C(R7)-, cuando L es =N-; o M es =N-, cuando L es =C(H)-; R1 es -CN, piridinilo sin sustituir, piridinilo sustituido por alquilo C1-4 o el correspondiente N-óxido de piridina; R2 es hidrógeno, halógeno, alquilo C1-4 o cicloalquilo C3-6; R3 es hidrógeno, halógeno, alquilo C1-4 o cicloalquilo C3-6; R4 es hidrógeno, halógeno, alquilo C1-4 sin sustituir o alquilo C1-4 sustituido por flúor, alcoxi C1-4 sin sustituir o alcoxi C1-4 sustituido por flúor, cicloalquilo C3- 6 sin sustituir o cicloalquilo C3-6 sustituido por flúor; R5 es hidrógeno, halógeno, alquilo C1-4 sin sustituir o alquilo C1-4 sustituido por flúor, cicloalquilo C3-6 sin sustituir o cicloalquilo C3-6 sustituido por flúor; R6 es hidrógeno o halógeno; y R7 es hidrógeno, alquilo C1-4 sin sustituir o alquilo C1-4 sustituido por CN, cicloalquilo C3-6 sin sustituir o cicloalquilo C3-6 sustituido por CN, con la condición de que cuando A es =C(R4)-, D es =C(H)-, E es =C(H)-, L es =N-, R1 es - CN, R2 es hidrógeno, R3 es hidrógeno, y a) M es =C(H)-, R4 no es hidrógeno, cloro o metoxi; o b) M es =C(CH3)-, R4 no es hidrógeno, y sus sales de adición farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03078075 | 2003-10-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045959A1 true AR045959A1 (es) | 2005-11-16 |
Family
ID=34486287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103565A AR045959A1 (es) | 2003-10-03 | 2004-10-01 | Derivados de pirazolo- e imidazo-pirimidina |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7329662B2 (es) |
| EP (1) | EP1670801B1 (es) |
| JP (1) | JP4551402B2 (es) |
| KR (2) | KR100781469B1 (es) |
| CN (2) | CN101239981B (es) |
| AR (1) | AR045959A1 (es) |
| AT (1) | ATE512148T1 (es) |
| AU (1) | AU2004283801B2 (es) |
| BR (1) | BRPI0414948A (es) |
| CA (1) | CA2540768C (es) |
| CO (1) | CO5680437A2 (es) |
| ES (1) | ES2364753T3 (es) |
| IL (1) | IL174512A0 (es) |
| MX (1) | MXPA06003526A (es) |
| NO (1) | NO20061363L (es) |
| NZ (1) | NZ546037A (es) |
| RU (1) | RU2350616C2 (es) |
| TW (1) | TWI297691B (es) |
| WO (1) | WO2005040171A1 (es) |
| ZA (1) | ZA200602677B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7329662B2 (en) * | 2003-10-03 | 2008-02-12 | Hoffmann-La Roche Inc. | Pyrazolo-pyridine |
| RU2378277C2 (ru) | 2004-06-21 | 2010-01-10 | Ф. Хоффманн-Ля Рош Аг | Производные пиразолпиримидина |
| JP4708438B2 (ja) * | 2005-02-11 | 2011-06-22 | エフ．ホフマン−ラ ロシュ アーゲー | ｍＧｌｕＲ２アンタゴニストとしてのピラゾロピリミジン誘導体 |
| CN101180299B (zh) | 2005-03-23 | 2010-12-15 | 弗·哈夫曼-拉罗切有限公司 | 作为mglur2拮抗剂的乙炔基-吡唑并嘧啶衍生物 |
| BRPI0616571A2 (pt) | 2005-09-27 | 2011-06-21 | Hoffmann La Roche | oxadiazolil pirazol-piridiminas como antagonistas de mglur2, processo para sua preparação, composição farmacêutica que os contém e uso dos mesmo |
| EP2178375B1 (en) * | 2007-07-20 | 2014-09-24 | Merck Sharp & Dohme Corp. | Pyrazoloý1,5-a¨pyrimidine derivatives |
| CN101671336B (zh) * | 2009-09-23 | 2013-11-13 | 辽宁利锋科技开发有限公司 | 芳杂环并嘧啶衍生物和类似物及其制备方法和用途 |
| US9447099B2 (en) * | 2011-10-04 | 2016-09-20 | Hoffmann-La Roche Inc. | Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine |
| US20150197503A1 (en) * | 2012-07-27 | 2015-07-16 | Bial-Portela & Cª, S.A. | Process for the synthesis of substituted urea compounds |
| MX2015004604A (es) | 2012-10-23 | 2015-10-08 | Hoffmann La Roche | Antagonistas de los receptores metabotropicos de glutamato 2/3 (mglu2/3) para el tratamiento de los trastornos autistas. |
| MY182036A (en) | 2013-02-21 | 2021-01-18 | Sunshine Lake Pharma Co Ltd | Heteroaromatic compounds as pi3 kinase modulators |
| TW201542550A (zh) * | 2013-09-06 | 2015-11-16 | Lexicon Pharmaceuticals Inc | 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法 |
| CN104193745B (zh) * | 2014-07-30 | 2016-09-28 | 斯芬克司药物研发（天津）股份有限公司 | 一种咪唑并嘧啶羧酸类化合物及其制备方法 |
| CN107018661B (zh) * | 2014-08-01 | 2020-01-03 | 詹森药业有限公司 | 6,7-二氢吡唑并[1,5-a]吡嗪-4(5H)-酮化合物及其作为MGLUR2受体的负向别构调节剂的用途 |
| EP3000814A1 (en) | 2014-09-26 | 2016-03-30 | Domain Therapeutics | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors |
| WO2016087489A1 (en) * | 2014-12-03 | 2016-06-09 | Janssen Pharmaceutica Nv | Radiolabelled mglur2 pet ligands |
| TWI713497B (zh) * | 2015-02-26 | 2020-12-21 | 南韓商愛思開生物製藥股份有限公司 | 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物 |
| AU2016311426B2 (en) | 2015-08-26 | 2021-05-20 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to NTRK |
| EP3377497A1 (en) * | 2015-11-19 | 2018-09-26 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
| EP3389728B1 (en) | 2015-12-18 | 2020-08-05 | Janssen Pharmaceutica NV | Radiolabelled mglur2/3 pet ligands |
| PL3389727T3 (pl) | 2015-12-18 | 2021-02-08 | Janssen Pharmaceutica Nv | RADIOZNAKOWANE LIGANDY mGluR2/3 DO PET |
| TWI795510B (zh) * | 2018-01-17 | 2023-03-11 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | PI4KIIIβ抑制劑 |
| WO2025002289A1 (zh) * | 2023-06-29 | 2025-01-02 | 湖南九典制药股份有限公司 | 一种吡唑并杂芳基类化合物及其制备方法和应用 |
| CN116836110A (zh) * | 2023-06-30 | 2023-10-03 | 天津均凯农业科技有限公司 | 一种2-氨乙基-3-氯-5-三氟甲基吡啶盐酸盐的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ244598A3 (cs) | 1996-02-07 | 1998-10-14 | Janssen Pharmaceutica N.V. | Pyrazolopyrimidiny jako antagonisty CRF receptoru |
| NZ333777A (en) * | 1996-07-24 | 2000-07-28 | Du Pont Pharm Co | (1,5-a) pyrazolo and triazole triazines and pyrimidines |
| ATE214704T1 (de) * | 1997-07-18 | 2002-04-15 | Hoffmann La Roche | 5h-thiazolo(3,2-a)pyrimidinderivate |
| AU4203500A (en) | 1999-04-06 | 2000-10-23 | Du Pont Pharmaceuticals Company | Pyrazolopyrimidines as crf antagonists |
| JP4071115B2 (ja) | 2001-04-12 | 2008-04-02 | エフ．ホフマン−ラ ロシュ アーゲー | ｍＧｌｕＲ２アンタゴニストＩＩとしてのジヒドロ−ベンゾ〔ｂ〕〔１，４〕ジアゼピン−２−オン誘導体 |
| GB0128499D0 (en) | 2001-11-28 | 2002-01-23 | Merck Sharp & Dohme | Therapeutic agents |
| EP1453815A4 (en) * | 2001-11-30 | 2005-04-06 | Merck & Co Inc | METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS |
| US7329662B2 (en) * | 2003-10-03 | 2008-02-12 | Hoffmann-La Roche Inc. | Pyrazolo-pyridine |
-
2004
- 2004-09-24 US US10/948,970 patent/US7329662B2/en not_active Expired - Fee Related
- 2004-09-27 RU RU2006114749/04A patent/RU2350616C2/ru not_active IP Right Cessation
- 2004-09-27 WO PCT/EP2004/010807 patent/WO2005040171A1/en not_active Ceased
- 2004-09-27 MX MXPA06003526A patent/MXPA06003526A/es active IP Right Grant
- 2004-09-27 NZ NZ546037A patent/NZ546037A/en unknown
- 2004-09-27 ES ES04765633T patent/ES2364753T3/es not_active Expired - Lifetime
- 2004-09-27 AU AU2004283801A patent/AU2004283801B2/en not_active Ceased
- 2004-09-27 EP EP04765633A patent/EP1670801B1/en not_active Expired - Lifetime
- 2004-09-27 KR KR1020067006303A patent/KR100781469B1/ko not_active Expired - Fee Related
- 2004-09-27 CN CN2008100836319A patent/CN101239981B/zh not_active Expired - Fee Related
- 2004-09-27 CN CNB2004800357899A patent/CN100522964C/zh not_active Expired - Fee Related
- 2004-09-27 AT AT04765633T patent/ATE512148T1/de active
- 2004-09-27 KR KR1020077018904A patent/KR20070096033A/ko not_active Ceased
- 2004-09-27 BR BRPI0414948-3A patent/BRPI0414948A/pt not_active IP Right Cessation
- 2004-09-27 CA CA2540768A patent/CA2540768C/en not_active Expired - Fee Related
- 2004-09-27 JP JP2006530027A patent/JP4551402B2/ja not_active Expired - Fee Related
- 2004-09-30 TW TW093129636A patent/TWI297691B/zh active
- 2004-10-01 AR ARP040103565A patent/AR045959A1/es unknown
-
2006
- 2006-03-23 IL IL174512A patent/IL174512A0/en not_active IP Right Cessation
- 2006-03-24 NO NO20061363A patent/NO20061363L/no not_active Application Discontinuation
- 2006-03-31 ZA ZA200602677A patent/ZA200602677B/en unknown
- 2006-04-03 CO CO06032493A patent/CO5680437A2/es not_active Application Discontinuation
-
2007
- 2007-02-16 US US11/707,480 patent/US7514443B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR045959A1 (es) | Derivados de pirazolo- e imidazo-pirimidina | |
| ATE302775T1 (de) | Carbolinderivate | |
| NO20071642L (no) | N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger | |
| MX2007000505A (es) | Derivados de oxindol sustituidos y medicamentos que contienen los mismos. | |
| NO331013B1 (no) | Nye forbindelser som er anti-inflammasjons, immunomodulerende og anti-proliferative midler, anvendelse av forbindelsene samt farmasoytisk preparat | |
| NO20050870L (no) | Fosfodiesterase 4-inhibitorer, inkludert N-substituerte anilin- og difenylaminanaloger | |
| NO20074641L (no) | 1-Acetic Acid-Indole Derivatives with PGD2 Antagonist Activity | |
| HRP20090281T1 (hr) | 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti | |
| ATE537830T1 (de) | Nicotinamid derivate und ihre verwendung als therapeutika | |
| ATE449099T1 (de) | Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren | |
| ATE346067T1 (de) | Carbolinderivate | |
| EA200601686A1 (ru) | Замещенные производные морфолина и тиоморфолина | |
| NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
| NO20062892L (no) | 7-fenylalkyl-substituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)-polymeraseinhibitorer | |
| DE602005023015D1 (de) | Indolderivate als viruzide | |
| NO20070565L (no) | Kinolin tiazolinoner med CDK1 antiproliferativ aktivitet | |
| NO20054787D0 (no) | Indenderivater som farmasotiske midler | |
| MXPA05009282A (es) | Derivados de anilina sustituidos. | |
| MX2024012018A (es) | Inhibidores de malt-1 de tiazolo[5,4-b]piridina | |
| ATE414516T1 (de) | Morphinanderivate als mittel gegen juckreiz | |
| AR041898A1 (es) | Derivados de 4(fenil-piperazinil-metil) benzamida y sus usos para el tratamiento del dolor y desordenes gastrointestinales | |
| NO20050871L (no) | 6-amino-1H-indazol- og 4-aminobenzofuranforbindelser som fosfodiesterase 4-inhibitorer | |
| NO20071230L (no) | Oksazolidinoner inneholdende oksindoler som antibakterielle midler | |
| NO20064632L (no) | Tricykliske imidazopyridiner | |
| NO20063220L (no) | Tricykliske imidazopyridiner for anvendelse som gastriske sekresjonsinhibitorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |